Last €10.09 EUR
Change Today -0.027 / -0.27%
Volume 0.0
TCE1 On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 2:08 AM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

celldex therapeutics inc (TCE1) Snapshot

Open
€10.09
Previous Close
€10.11
Day High
€10.09
Day Low
€10.08
52 Week High
10/2/13 - €28.29
52 Week Low
05/9/14 - €7.89
Market Cap
901.2M
Average Volume 10 Days
416.5
EPS TTM
--
Shares Outstanding
89.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CELLDEX THERAPEUTICS INC (TCE1)

Related News

No related news articles were found.

celldex therapeutics inc (TCE1) Related Businessweek News

No Related Businessweek News Found

celldex therapeutics inc (TCE1) Details

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. Its lead drug candidates include rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma and a Phase II study for the treatment of recurrent glioblastoma; and Glembatumumab vedotin (CDX-011) is a targeted antibody-drug conjugate in a randomized study for the treatment of triple negative breast cancer. The company also has various earlier stage drug candidates in clinical development, including varlilumab (CDX-1127), a fully human therapeutic monoclonal antibody for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-1401, a targeted immunotherapeutic aimed at antigen presenting cells for cancer indications. Its preclinical product candidate includes CDX-014, a human monoclonal antibody-drug conjugate that targets TIM-1, a molecule that is expressed on renal and ovarian cancers with minimal expression in normal tissues. The company has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; Duke University Brain Tumor Cancer Center; Ludwig Institute for Cancer Research; University of Southampton; Amgen Inc.; Amgen Fremont; Seattle Genetics, Inc.; and Bristol-Myers Squibb Company. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

120 Employees
Last Reported Date: 03/3/14

celldex therapeutics inc (TCE1) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $871.4K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $437.7K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $589.4K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $553.5K
Chief Business Officer and Senior Vice Presid...
Total Annual Compensation: $411.7K
Compensation as of Fiscal Year 2013.

celldex therapeutics inc (TCE1) Key Developments

Oncothyreon Inc. Enters into Phase I Co-Development Agreement with Celldex Therapeutics, Inc

On May 28, 2014, Oncothyreon Inc. entered into a phase I co-development agreement with Celldex Therapeutics, Inc. Pursuant to the agreement, the company and Celldex agreed to collaborate on a combined clinical trial of ONT-10 and varlilumab. The planned trial is an open-label Phase 1b study of ONT-10 administered at the recommended single agent dose in combination with varlilumab at two dose levels in up to 42 patients with advanced breast or ovarian cancer. The primary objective of the trial is to determine the safety and tolerability of the combined therapy. The agreement provides that the company will supply ONT-10 and Celldex will supply CDX-1127. The Phase 1b trial will be conducted and funded by the company. The company and Celldex will jointly own the data from the trial and will make any plans for potential future development of the combination therapy together. Under the agreement, neither the company nor Celldex has granted the other a license, or any other rights, to its product candidate. The agreement will continue until the completion of the Phase 1b trial, but may be terminated earlier upon written notice from either party or breach of the agreement.

Celldex Therapeutics' Varlilumab Continues to Demonstrate Very Favorable Profile

Celldex Therapeutics, Inc. reported data from its ongoing Phase 1 study of the fully human monoclonal antibody varlilumab (CDX-1127) in cancer. Varlilumab is an immunotherapy designed to enhance the body's natural immune response by directly activating T cells that can specifically recognize and kill cancer cells. Preclinical data support the broad study of varlilumab in combination with a number of other anti-cancer agents including but not limited to checkpoint inhibitors, chemotherapies, targeted therapies and vaccines. Varlilumab will enter at least four combination studies in the second half of 2014. Results presented included data from the lymphoid malignancies dose-escalation arm and solid tumor expansion cohorts in metastatic melanoma and renal cell carcinoma. Varlilumab was very well tolerated and demonstrated clear biologic activity and promising signs of clinical activity in advanced, treatment-refractory patient populations--all of which provide the rationale for combination studies with other immune activating therapies.

Celldex Therapeutics, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 10:30 AM

Celldex Therapeutics, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 10:30 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Anthony S. Marucci, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TCE1:GR €10.09 EUR -0.027

TCE1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TCE1.
View Industry Companies
 

Industry Analysis

TCE1

Industry Average

Valuation TCE1 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLDEX THERAPEUTICS INC, please visit www.celldextherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.